NEW YORK ( TheStreet) -- Integra LifeSciences Holdings (Nasdaq: IART) hit a new 52-week low Friday as it is currently trading at $35.80, below its previous 52-week low of $35.84 with 61,387 shares traded as of three p.m. ET. Average volume has been 236,800 shares over the past 30 days.

Integra LifeSciences has a market cap of $1.1 billion and is part of the health care sector and health services industry. Shares are down 17.8% year to date as of the close of trading on Thursday.

Integra LifeSciences Holdings Corporation develops, manufactures, and markets surgical implants and medical instruments for neurosurgery, extremity reconstruction, orthopedics, and general surgery. The company has a P/E ratio of 24.8, above the average health services industry P/E ratio of 24.6 and above the S&P 500 P/E ratio of 17.7.
  • Practice your IART trading strategies and win cash in our stock game.

TheStreet Ratings rates Integra LifeSciences as a hold. The company's strengths can be seen in multiple areas, such as its revenue growth, good cash flow from operations and expanding profit margins. However, as a counter to these strengths, we also find weaknesses including deteriorating net income and disappointing return on equity. You can view the full Integra LifeSciences Ratings Report.

See all 52-week low stocks or get investment ideas from our investment research center.
null

If you liked this article you might like

10 Favorite Healthcare Stocks for 2018: Medical Marijuana to Opioid Treatment

10 Favorite Healthcare Stocks for 2018: Medical Marijuana to Opioid Treatment

Johnson & Johnson Signals It Could Make Additional Divestitures

Johnson & Johnson Signals It Could Make Additional Divestitures

Integra's Massive Run-Up Expected to Continue as J&J's Surgical Business Joins the Fold

Integra's Massive Run-Up Expected to Continue as J&J's Surgical Business Joins the Fold

Integra Scoops up JNJ's Codman Neurosurgery for $1.05 Billion

Integra Scoops up JNJ's Codman Neurosurgery for $1.05 Billion

Integra Scoops Up JNJ's Codman Neurosurgery for $1.05 Billion

Integra Scoops Up JNJ's Codman Neurosurgery for $1.05 Billion